SHORT MINI FUTURE - NOVO-NORDISK B | Market Closed - Swiss Exchange 08:50:00 07/06/2024 pm IST | ||
| 0.46 CHF | -14.81% |
|
| Current month | -46.51% | ||
| 1 month | -62.60% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 07/24/07 | 0.46 | -14.81% |
| 06/24/06 | 0.54 | -30.77% |
| 04/24/04 | 0.78 | -8.24% |
| 03/24/03 | 0.85 | -1.16% |
Delayed Quote Swiss Exchange
Last update June 07, 2024 at 08:50 pm IST
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| MNOA8V | |
| ISIN | CH1325146087 |
| Date issued | 20/03/2024 |
| Strike | 1,050 kr |
| Maturity | Unlimited |
| Parity | 20 : 1 |
| Emission price | 1.07 CHF |
| Emission volume | N/A |
| Settlement | cash |
| Currency | CHF |
Technical Indicators
| Highest since issue | 1.26 CHF |
|---|---|
| Lowest since issue | 0.46 CHF |
| Spread | 0.04 CHF |
| Spread % | 8.70% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
984
DKK
Average target price
920.8
DKK
Spread / Average Target
-6.43%
- Stock Market
- Certificates
- MNOA8V Certificat
